Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | NNMT | P40261 | 2/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.34 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ACVR2A | P27037 | 1/20 | 0.32 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29952389 | 1.00 | POLB (0.36) | POLBTDP1NNMTENPP2TXNRD1 | |
| SCHEMBL22281202 | 0.89 | POLB (0.34) | POLBTDP1NNMTTXNRD1SIRT2 | |
| SCHEMBL16294781 | 0.77 | POLB (0.38) | POLBTDP1NNMTENPP2TXNRD1 | |
| SCHEMBL19364178 | 0.77 | POLB (0.38) | POLBTDP1NNMTTXNRD1KDM4E | |
| SCHEMBL29956451 | 0.77 | POLB (0.38) | POLBTDP1NNMTENPP2TXNRD1 | |
| SCHEMBL29653296 | 0.75 | NNMT (0.50) | POLBTDP1NNMTENPP2ALDH1A1 | |
| SCHEMBL248283 | 0.75 | NNMT (0.50) | POLBTDP1NNMTENPP2ALDH1A1 | |
| SCHEMBL17586768 | 0.75 | TXNRD1 (0.36) | POLBTDP1NNMTTXNRD1SIRT2 | |
| SCHEMBL15077682 | 0.75 | KMT2A (0.42) | POLBTDP1NNMTTXNRD1ALDH1A1 | |
| SCHEMBL321488 | 0.75 | POLB (0.52) | POLBTDP1NNMTENPP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3433258-B1 | PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR | AFFERENT PHARMACEUTICALS INC (US) | 2023-07-19 | — | — | EP | disclosed |
| EP-3430000-B1 | PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR | AFFERENT PHARMACEUTICALS INC (US) | 2022-12-28 | — | — | EP | disclosed |
| US-10822311-B2 | Pyrimidines and variants thereof, and uses therefor | Afferent Pharmaceuticals, Inc. (US) | 2020-11-03 | — | — | US | disclosed |
| US-10662162-B2 | Pyrimidines and variants thereof, and uses therefor | Afferent Pharmaceuticals, Inc. (US) | 2020-05-26 | — | — | US | disclosed |
| US-20190055202-A1 | PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR | AFFERENT PHARMACEUTICALS INC. (US) | 2019-02-21 | — | — | US | disclosed |
| WO-2017165255-A1 | PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR | AFFERENT PHARMACEUTICALS INC. (US) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017160569-A1 | PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR | AFFERENT PHARMACEUTICALS INC. (US) | 2017-09-21 | — | — | WO | disclosed |
| US-20060199823-A1 | Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands | NEUROGEN CORPORATION (US) | 2006-09-07 | — | — | US | disclosed |
| EP-1680424-A2 | HETEROARYL FUSED PYRIDINES, PYRAZINES AND PYRIMIDINES AS CRF1 RECEPTOR LIGANDS | Neurogen Corporation (US) | 2006-07-19 | — | — | EP | disclosed |
| EP-1675858-A2 | 5-ARYL-PYRAZOLO [4,3-D] PYRIMIDINES, PYRIDINES, AND PYRAZINES AND RELATED COMPOUNDS | NEUROGEN CORPORATION (US) | 2006-07-05 | — | — | EP | disclosed |
| US-20050113379-A1 | Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands | AVENTIS PHARMACEUTICALS, INC. | 2005-05-26 | — | — | US | disclosed |
| WO-2005028480-A2 | 5-ARYL-PYRAZOLO[4,3-D]PYRIMIDINES, PYRIDINES, AND PYRAZINES AND RELATED COMPOUNDS | NEUROGEN CORPORATION (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20050070542-A1 | 5-Aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds | NEUROGEN CORPORATION | 2005-03-31 | — | — | US | disclosed |
| WO-2005023806-A2 | HETEROARYL FUSED PYRIDINES, PYRAZINES AND PYRIMIDINES AS CRF1 RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070542-A1 | 5-Aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds | CRHR1, HTR5A, HTR1D | POLB 4030/4885TDP1 1057/4885NNMT 3488/4885 |
| US-10662162-B2 | Pyrimidines and variants thereof, and uses therefor | P2RX3, P2RX7, P2RX1 | POLB 2200/4885TDP1 379/4885NNMT 2584/4885 |
| US-20060199823-A1 | Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands | CRHR1, CRHR2, HTR5A | POLB 4347/4885TDP1 1559/4885NNMT 3825/4885 |
| US-10822311-B2 | Pyrimidines and variants thereof, and uses therefor | P2RX3, P2RX5, P2RX4 | POLB 1896/4885TDP1 304/4885NNMT 1626/4885 |
| US-20190055202-A1 | PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR | P2RX3, P2RX7, P2RX1 | POLB 2200/4885TDP1 379/4885NNMT 2584/4885 |
| US-20050113379-A1 | Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands | CRHR1, CRHR2, HTR5A | POLB 4347/4885TDP1 1559/4885NNMT 3825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.